Wegovy in the UK:
Complete Guide

What is Wegovy?

Wegovy is a prescription weight management medicine containing semaglutide at a higher dose than its sister product Ozempic. Manufactured by Novo Nordisk, Wegovy is the first GLP-1 receptor agonist to be specifically licensed for chronic weight management in the UK.

The medication works by mimicking the GLP-1 hormone naturally produced in the gut. It acts on areas of the brain that regulate appetite and food intake, reducing hunger and helping patients feel satisfied with smaller portions. The maintenance dose of 2.4 mg is higher than the maximum Ozempic dose of 2 mg, reflecting its optimisation for weight loss rather than glycaemic control.

In the landmark STEP clinical trial programme, participants taking Wegovy alongside lifestyle interventions achieved an average weight reduction of approximately 15 to 17 per cent of their body weight over 68 weeks. The SELECT cardiovascular outcomes trial also demonstrated a 20 per cent reduction in major adverse cardiovascular events in overweight or obese adults without diabetes.

NHS eligibility for Wegovy

NICE published technology appraisal guidance (TA875) recommending semaglutide for weight management on the NHS, subject to specific criteria. Wegovy is available through NHS specialist weight management services, not directly from GPs.

NICE eligibility criteria

To qualify for Wegovy on the NHS, patients must meet all of the following:

• A BMI of 35 or above, or a BMI of 30 to 34.9 with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, obstructive sleep apnoea or cardiovascular disease)
• Referral to and management within a specialist weight management service (Tier 3 or equivalent)
• Participation in a structured behavioural intervention programme alongside medication
• BMI thresholds may be adjusted downwards by 2.5 kg/m² for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or Black Caribbean ethnic backgrounds

Treatment duration and review

NHS treatment with Wegovy is subject to regular clinical review. NICE recommends that treatment should be continued only if the patient achieves at least 5 per cent weight loss after 6 months on the maintenance dose. If this threshold is not met, the clinical team will discuss whether to continue or discontinue treatment.

Private clinics and providers

For patients who do not meet NHS criteria or wish to avoid waiting times, Wegovy is available through private healthcare providers. The UK market includes both online digital health platforms and traditional private clinics.

Comparison of UK private providers

When choosing a private provider, ensure the pharmacy is registered with the GPhC and the prescribing clinician is registered with the GMC or GPhC as appropriate. Beware of unregulated sources offering semaglutide at unusually low prices, as counterfeit medications have been identified by the MHRA.

Dosage schedule

Wegovy uses a 16-week dose-escalation protocol to minimise gastrointestinal side effects before reaching the maintenance dose:

1. Weeks 1–4: 0.25 mg once weekly
2. Weeks 5–8: 0.5 mg once weekly
3. Weeks 9–12: 1 mg once weekly
4. Weeks 13–16: 1.7 mg once weekly
5. Week 17 onwards: 2.4 mg once weekly (maintenance dose)

Each dose level uses a separate pre-filled pen. Your prescriber will provide a prescription for the appropriate pen at each stage of the escalation. If you experience significant side effects at any step, your clinician may extend the time at that dose before increasing further.

How effective is Wegovy?

The clinical evidence for Wegovy comes primarily from the STEP (Semaglutide Treatment Effect in People with obesity) trial programme, which enrolled over 16,000 participants across multiple studies.

Key clinical results

• STEP 1: Average weight loss of 14.9 per cent at 68 weeks (compared with 2.4 per cent with placebo)
• STEP 2 (type 2 diabetes): Average weight loss of 9.6 per cent at 68 weeks
• STEP 3 (with intensive behavioural therapy): Average weight loss of 16 per cent at 68 weeks
• STEP 5 (long-term): Weight loss maintained at 2 years with continued treatment
• SELECT (cardiovascular): 20 per cent reduction in major adverse cardiovascular events in overweight/obese adults without diabetes

It is important to note that individual results vary considerably. Some patients achieve greater weight loss, while others may respond less strongly. Sustained dietary and lifestyle changes alongside medication are associated with the best outcomes.

Side effects

Wegovy shares the same side effect profile as other semaglutide products. The most common adverse effects are gastrointestinal and tend to be most pronounced during the dose-escalation phase.

Most common side effects

• Nausea (reported by approximately 44 per cent of participants in clinical trials)
• Diarrhoea
• Vomiting
• Constipation
• Abdominal pain
• Headache
• Fatigue

These side effects typically improve over several weeks. The gradual dose escalation is specifically designed to reduce their severity. For detailed guidance on managing side effects, see our GLP-1 side effects guide.

Serious side effects (rare)

• Pancreatitis
• Gallbladder disease (including gallstones and cholecystitis)
• Acute kidney injury (secondary to dehydration)
• Suicidal ideation (under ongoing pharmacovigilance review by the MHRA)

Who should not take Wegovy?

Wegovy is contraindicated in the following groups:

• People with a personal or family history of medullary thyroid carcinoma or MEN 2
• Known hypersensitivity to semaglutide
• Pregnant or breastfeeding women (reliable contraception required during treatment and for at least 2 months after stopping)
• People under 18 years of age (not licensed for paediatric use in the UK at this time)

Caution is advised for patients with a history of pancreatitis, severe hepatic impairment, severe renal impairment, or existing diabetic retinopathy. Your prescriber will assess your suitability on an individual basis.

Wegovy vs Ozempic: what is the difference?

Both Wegovy and Ozempic contain semaglutide, but they are licensed for different indications and prescribed at different doses. Ozempic (maximum 2 mg) is indicated for type 2 diabetes, while Wegovy (2.4 mg) is specifically approved for weight management. The higher maintenance dose in Wegovy produces greater appetite suppression and, on average, more weight loss. Your clinician will recommend the appropriate product based on your primary treatment goal.

For a full comparison including Mounjaro, see our weight loss injections comparison.

Frequently asked questions

How long do I need to take Wegovy?

Wegovy is intended as a long-term treatment. Clinical evidence shows that weight regain is common after discontinuation. NICE recommends that treatment should be reviewed at regular intervals, with continuation based on clinical benefit. Your prescriber will discuss an appropriate treatment duration based on your response and individual circumstances.

Can I take Wegovy if I have type 2 diabetes?

Yes, semaglutide can be used in people with type 2 diabetes. However, your clinician will need to consider whether Wegovy or Ozempic is more appropriate, and may need to adjust your other diabetes medications (particularly insulin or sulphonylureas) to reduce the risk of hypoglycaemia.

Is Wegovy safe long-term?

Long-term data from clinical trials extending to 2 years supports the safety and efficacy of continued Wegovy treatment. The SELECT trial demonstrated cardiovascular benefits over a median follow-up of approximately 40 months. Post-marketing pharmacovigilance by the MHRA continues to monitor for any emerging safety signals.